Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Hanns-Ulrich Marschall

Professor/ chief physician

Hanns-Ulrich Marschall
Professor/ chief physician
hanns-ulrich.marschall@gu.se

Postal Address: Su sahlgrenska, 41345 Göteborg
Visiting Address: Magtarmlab , Göteborg


Department of Molecular and Clinical Medicine at Institute of Medicine (More Information)
SU Sahlgrenska
413 45 Göteborg
Fax: +46 31823762
Visiting Address: Blå stråket 5 B Wallenberglab/SU , 413 45 Göteborg

About Hanns-Ulrich Marschall

Hanns-Ulrich Marschall, MD, PhD, MSc, is since 2010 Professor of Clinical Hepatology at Gothenburg University. He was Professor of Medical Gastroentology and Hepatology at the Karolinska Institute in Stockholm 2007-2010. He is a leading expert in bile acid metabolism and his research involves animal and human studies with focus on the interaction between bile acids and the gut microbiota at the Wallenberg Laboratory. He is also actively involved in a large number of sponsored and investigator-initiated clinical trials focusing on the development of new treatment options for non-alcoholic fatty liver disease/steatohepatitis and cholestatic liver diseases such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and in particular, intrahepatic cholestasis of pregnancy (ICP).

Main research

The farnesoid X receptor (FXR) is a nuclear transcription factor that is activated by bile acids and feedback-regulates bile acid and lipid metabolism. Extensive research over the past decade has placed specific FXR activation at the center of promising novel treatment options for cholestatic liver disorders and metabolic diseases such as type 2 diabetes, atherosclerosis and, in particular, non-alcoholic steatohepatitis.

To date, FXR activation studies have been conducted in animal models of cholestatic and fatty liver diseases and only subsequently translated into models of human relevance, mainly ex vivo/in vitro human cell systems. However, this strategy might miss important mechanistic insights since bile acid species (i.e. potential FXR ligands) differ profoundly between humans and mice. Moreover, bile acids activate several other FXR-independent metabolic signaling pathways and some might even act as FXR antagonists. Furthermore, the gut microbiota regulates species-specific secondary bile acid metabolism. Thus, changes in FXR-activated feedback loops might be differently translated between humans and rodents and depend on specific gut microbiota.

We aim to improve the translation of animal model studies on FXR activation to human diseases by identifying specific differences in FXR-dependent regulatory pathways between mice and humans and by comparing global DNA binding sites of FXR in mouse and human liver genomes. Our ultimate goal is to develop new treatment options for human cholestatic and fatty liver diseases.

Group Members

  • Annika Wahlström, PhD, Researcher
  • Johan Waern, MD, PhD, Postdoctoral Fellow
  • Samer Al-Dury, MD, PhD student
  • Niclas Björnfot, Registered Study Nurse
  • Olivia Jungstrand, Administrator

Key publications

Krones E, Eller K, Pollheimer MJ, Racedo S, Kirsch AH, Frauscher B, Wahlström A, Ståhlman M, Trauner M, Grahammer F, Huber TB, Wagner K, Rosenkranz AR, Marschall HU, Fickert P.
NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.
J Hepatol doi: 10.1016/j.jhep.2017.02.019 (2017).

Wahlström A, Kovatcheva-Datchary P, Ståhlman M, Khan MT, Bäckhed F, Marschall HU.
Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota.
J Lipid Res. 58:412-419 (2017).

Fuchs CD, Paumgartner G, Wahlström A, Schwabl P, Reiberger T, Leditznig N, Stojakovic T, Rohr-Udilova N, Chiba P, Marschall HU, Trauner M.
Metabolic preconditioning protects BSEP/ABCB11(-/-) mice against cholestatic liver injury.
J Hepatol. 66:95-101 (2017).

Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group.
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
N Engl J Med. 375:631-43 (2016).

Wahlström A, Sayin SI, Marschall HU, Bäckhed F.
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism.
Cell Metab. 24:41-50 (2016).

Kummen M, Holm K, Anmarkrud JA, Nygård S, Vesterhus M, Høivik ML, Trøseid M, Marschall HU, Schrumpf E, Moum B, Røsjø H, Aukrust P, Karlsen TH, Hov JR.
The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.
Gut. doi: 10.1136/gutjnl-2015-310500 (2016).

Baghdasaryan A, Fuchs CD, Österreicher CH, Lemberger UJ, Halilbasic E, Påhlman I, Graffner H, Krones E, Fickert P, Wahlström A, Ståhlman M, Paumgartner G, Marschall HU, Trauner M.
Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
J Hepatol. 64:674-81 (2016).

Graffner H, Gillberg PG, Rikner L, Marschall HU.
The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation.
Aliment Pharmacol Ther. 43:303-10 (2016).

Wikström Shemer EA, Stephansson O, Thuresson M, Thorsell M, Ludvigsson JF, Marschall HU.
Intrahepatic cholestasis of pregnancy and cancer, immune-mediated
and cardiovascular diseases: A population-based cohort study.

J Hepatol. 63:456-61 (2016).

Marschall HU, Wikström Shemer E, Ludvigsson JF, Stephansson O.
Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study.
Hepatology. 58:1385-91 (2013).

Latest publications

Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study
L. B. Manna, C. Ovadia, A. Lovgren-Sandblom, J. Chambers, S. Begum et al.
Bjog-an International Journal of Obstetrics and Gynaecology, Journal article 2019
Journal article

Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort.
Hanns-Ulrich Marschall, Ida Henriksson, Sara Lindberg, Fabian Söderdahl, Marcus Thuresson et al.
Scientific reports, Journal article 2019
Journal article

Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans.
Emmelie Cansby, Nagaraj M. Kulkarni, Elin Magnusson, Yeshwant Kurhe, Manoj Amrutkar et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Journal article 2019
Journal article

AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease.
Nikolaos Nikolaou, Laura L Gathercole, Lea Marchand, Sara Althari, Niall J Dempster et al.
Metabolism: clinical and experimental, Journal article 2019
Journal article

Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes.
Saraid McIlvride, Vanya Nikolova, Hei Man Fan, Julie A K McDonald, Annika Wahlström et al.
American journal of physiology. Endocrinology and metabolism, Journal article 2019
Journal article

Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
Lijun Liao, Kai Markus Schneider, Eric J C Galvez, Mick Frissen, Hanns-Ulrich Marschall et al.
Gut, Journal article 2019
Journal article

A Comprehensive FXR Signaling Atlas Derived from Pooled ChIP-seq Data.
Emilian Jungwirth, Katrin Panzitt, Hanns-Ulrich Marschall, Martin Wagner, Gerhard G Thallinger
Studies in health technology and informatics, Journal article 2019
Journal article

Showing 1 - 10 of 104

2019

Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study
L. B. Manna, C. Ovadia, A. Lovgren-Sandblom, J. Chambers, S. Begum et al.
Bjog-an International Journal of Obstetrics and Gynaecology, Journal article 2019
Journal article

Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort.
Hanns-Ulrich Marschall, Ida Henriksson, Sara Lindberg, Fabian Söderdahl, Marcus Thuresson et al.
Scientific reports, Journal article 2019
Journal article

Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans.
Emmelie Cansby, Nagaraj M. Kulkarni, Elin Magnusson, Yeshwant Kurhe, Manoj Amrutkar et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Journal article 2019
Journal article

AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease.
Nikolaos Nikolaou, Laura L Gathercole, Lea Marchand, Sara Althari, Niall J Dempster et al.
Metabolism: clinical and experimental, Journal article 2019
Journal article

Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes.
Saraid McIlvride, Vanya Nikolova, Hei Man Fan, Julie A K McDonald, Annika Wahlström et al.
American journal of physiology. Endocrinology and metabolism, Journal article 2019
Journal article

Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
Lijun Liao, Kai Markus Schneider, Eric J C Galvez, Mick Frissen, Hanns-Ulrich Marschall et al.
Gut, Journal article 2019
Journal article

A Comprehensive FXR Signaling Atlas Derived from Pooled ChIP-seq Data.
Emilian Jungwirth, Katrin Panzitt, Hanns-Ulrich Marschall, Martin Wagner, Gerhard G Thallinger
Studies in health technology and informatics, Journal article 2019
Journal article

Showing 1 - 10 of 104

Page Manager: Karin Allander|Last update: 9/19/2019
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?